Immunocore announces upcoming presentation and posters at ASCO 2024
24 avr. 2024 10h00 HE
|
Immunocore Holdings plc
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
05 janv. 2024 07h00 HE
|
Immunocore Holdings Limited
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn)...
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
07 nov. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major...
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
21 oct. 2023 08h45 HE
|
Immunocore Holdings Limited
Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01...
Immunocore announces upcoming presentation and posters at ESMO 2023
06 oct. 2023 07h01 HE
|
Immunocore Holdings Limited
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a...
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
03 août 2023 08h00 HE
|
Immunocore Holdings Limited
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 August 2023) Immunocore...
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
03 juin 2023 07h00 HE
|
Immunocore Holdings Limited
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3...
Immunocore to present at upcoming investor conferences
28 févr. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 28 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Immunocore is awarded the Prix Galien France award for KIMMTRAK
15 déc. 2022 06h00 HE
|
Immunocore Holdings Limited
Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye. (OXFORDSHIRE,...
Roca Therapeutics completes seed funding round
22 sept. 2022 01h00 HE
|
Roca Therapeutics
Roca Therapeutics completes seed funding round Series A funding round initiated to further fund the clinical development of its "First In Class" small molecules against Uveal Melanoma and other...